Clinical Trial Update: Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm [Phase 2]

View source ↗

Summary

Clinical trial update of a Phase 2 study evaluating venetoclax in combination with ASTX727 (oral decitabine/cedazuridine) for chronic myelomonocytic leukemia an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Myeloproliferative Neoplasm
• Myelodysplastic Syndrome
• Myelodysplastic Syndrome with Excess Blasts
• Myelomonocytic Leukemia
• Myeloproliferative Neoplasm

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)
• Venclexta (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: ACTIVE_NOT_RECRUITING